Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
AKLI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
accesswire.com
11 hours ago
accesswire.com
13 hours ago
Earnings Growth
YoY
Current
Estimates
Q2.22
N/A
-0.29
vs NA
Q3.22
N/A
-0.27
vs -0.23
Q4.22
N/A
-0.56
vs -0.25
Q1.23
N/A
-0.18
vs -0.28
Q2.23
N/A
-0.16
vs -0.29
Q3.23
N/A
-0.20
vs -0.27
Q4.23
N/A
-0.14
vs -0.56
Q1.24
N/A
-0.11
vs -0.18
Q3.24
N/A
-0.13
vs -0.20
Q4.24
N/A
-0.13
vs -0.14
Sales Growth
YoY
Current
Estimates
Q2.22
NA
64K vs NA
Q3.22
-47%
82K vs 155K
Q4.22
-31%
111K vs 161K
Q1.23
+71%
113K vs 66K
Q2.23
+78%
114K vs 64K
Q3.23
+756%
702K vs 82K
Q4.23
+575%
749K vs 111K
Q1.24
+239%
383K vs 113K
Q3.24
+28%
900K vs 702K
Q4.24
+34%
1M vs 749K
Return on Equity
QoQ
Q2.22
+25%
0.25
vs -0.09
Q3.22
+106%
1.06
vs 0.25
Q4.22
-15%
-0.15
vs 1.06
Q1.23
-25%
-0.25
vs -0.15
Q2.23
-14%
-0.14
vs -0.25
Q3.23
-23%
-0.23
vs -0.14
Q4.23
-19%
-0.19
vs -0.23
Q1.24
-19%
-0.19
vs -0.19
Institutionnal Ownership
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.00Â ( 0.25%)
Relative Strenght
95
Volume Buzz
-90%
Earning Acce
Yes
Dist 52w H.
65%Quote Panel
Key Metrics
Relative Strength
AKLI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
1362%2025-Revenue
-283%2025-EPS
45%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Morgan Stanley
initialisePrevious: Not converted
2022-12-28
Now: Equal-Weight
